Recurrent Ovarian Germ Cell Tumor Completed Phase 2 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0029793 (Recurrent Ovarian Germ Cell Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00467051Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell TumorsTreatment